Products

What will AGI do for Alefacept?

This classification denotes an immunosuppressant with the molecular formula C2306H3594N610O694S26, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) ELK3V90G6C, more generally known as alefacept. European Medicines Agency schedules alefacept in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20562. The term ALEFACEPT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 3-4, 2001, list 46). Most nations, for tariff and trade purposes, schedule alefacept under HS 30021095 and SITC 54163 (for the most current information on WCO designations on alefacept and salts thereof, please see Committee proceedings HSC/37, NC1059B2b Ann. O/3, 2006). As of Q4 2014, ALEFACEPT remains US FDA's Preferred Term for this commodity. Alefacept bears US NLM identifiers UMLS ID C0962603 and NCI Concept Code C65220. SMILES: C1C(=C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)CL.

How AGI delivers it

Four ways AGI delivers for Alefacept

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Alefacept, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Alefacept, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Alefacept connects

measured by

  • Aggregate Contentmodel
  • Bacterial Endotoxin Contentmodel
  • Bioassay Potencymodel
  • Protein Concentrationmodel
  • Protein Puritymodel
  • Reconstitution Timemodel